Mitral stenosis stages

Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]

Mitral Stenosis Microchapters

Home

Patient Information

Overview

Pathophysiology

Causes

Differentiating Mitral Stenosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Stages

History and Symptoms

Physical Examination

Electrocardiogram

Chest X Ray

Echocardiography

Cardiac MRI

Cardiac Catheterization

Treatment

Overview

Medical Therapy

Percutaneous Mitral Balloon Commissurotomy (PMBC)

Surgery

Follow Up

Prevention

Case Studies

Case #1

Mitral stenosis stages On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mitral stenosis stages

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA onMitral stenosis stages

CDC on Mitral stenosis stages

Mitral stenosis stages in the news

Blogs on Mitral stenosis stages

Directions to Hospitals Treating Mitral Stenosis

Risk calculators and risk factors for Mitral stenosis stages

Overview

According to the 2014 AHA/ACC guidelines for management of valvular heart diseases and valve morphology, the valve hemodynamics characteristics, the consequences of MS on the left atrium and the pulmonary arterial system, and base on the presence or absence of symptoms, there are 4 stages of mitral stenosis. Staging of mitral stenosis (MS) is of utmost importance because it dictates the appropriate management plan for the affected patients.

Stages of Mitral Stenosis

2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[1]

Table 16. Stages of MS

Stage Definition Valve anatomy Valve hemodynamics Hemodynamic consequences Symptoms
A At risk of MS ❑ Mild diastolic doming of mitral valve leaflets ❑ Normal transmitral velocity None None
B Progressive MS ❑ Rheumatic valve changes with commissural fusion and diastolic doming of the mitral valve leaflets Planimetered mitral valve area >1.5 cm2 ❑ Increased transmitral flow velocities
❑Mitral valve area >1.5 cm2
❑ Diastolic pressure half-time <150 ms
❑ Mild to moderate left atrial enlargement
❑ Normal pulmonary pressure at rest
None
C Asymptomatic severe MS Rheumatic valve changes characterized by commissural fusion and diastolic doming of mitral valve
❑ Planimetered mitral valve area ≤1.5 cm2
❑ Mitral valve area ≤1.5 cm2
❑ Diastolic pressure half-time ≥150 ms
❑ Severe left atrial enlargement
❑ Elevated PASP >50 mm Hg
None
D Symptomatic severe MS Rheumatic valve changes characterized by commissural fusion and diastolic doming of mitral valve
❑ Planimetered mitral valve area ≤1.5 cm2
❑ Mitral valve area ≤1.5 cm2
❑ Diastolic pressure half-time ≥150 ms
❑ Severe left atrial enlargement
❑ PASP > 50 mm Hg
❑Decreased exercise tolerance
❑ Exertional dyspnea


The transmitral mean pressure gradient should be obtained to further determine the hemodynamic effect of the MS and is usually >5 mm Hg to 10 mm Hg in severe MS; however, because of the variability of the mean pressure gradient with heart rate and forward flow, it has not been included in the criteria for severity.LA indicates left atrial; MS, mitral stenosis; and PASP, pulmonary artery systolic pressure.




According to the 2014 AHA/ACC guidelines for management of valvular heart diseases and valve morphology, the valve hemodynamics characteristics, the consequences of MS on the left atrium and the pulmonary arterial system, and base on the presence or absence of symptoms, there are 4 stages of mitral stenosis.[2]

Shown below is a table depicting the 4 stages of mitral stenosis, adapted from 2014 AHA/ACC guidelines for management of valvular heart diseases.[3]

Abbreviations: MS: mitral stenosis; MVA: mitral valve area; PASP: pulmonary artery systolic pressure

Stage Definition Valve anatomy Valve hemodynamics Hemodynamic consequences Symptoms
A At risk of MS ❑ Mild diastolic doming of mitral valve leaflets ❑ Normal transmitral velocity Absent Absent
B Progressive MS Rheumatic valve changes characterized by commissural fusion and diastolic doming of mitral valve
❑ MVA > 1.5 cm2 (planimetered)
❑ Increased transmitral flow velocities
MVA > 1.5 cm2
Pressure half time during diastole < 150 ms
❑ Mild to moderate left atrial enlargement
❑ Normal pulmonary pressure at rest
Absent
C Asymptomatic severe MS Rheumatic valve changes characterized by commissural fusion and diastolic doming of mitral valve
❑ MVA ≤ 1.5 cm2
❑ MVA ≤ 1 cm2 in very severe MS
❑ MVA ≤ 1.5 cm2 (planimetered)
❑ MVA ≤ 1 cm2 (planimetered) in very severe MS
Diastolic pressure half time ≥ 150 ms
Diastolic pressure half time ≥ 220 ms with very severe MS
❑ Severe left atrial enlargement
❑ PASP > 30 mm Hg
Absent
D Symptomatic severe MS Rheumatic valve changes characterized by commissural fusion and diastolic doming of mitral valve
❑ MVA ≤ 1.5 cm2 (planimetered)
❑ MVA ≤ 1.5 cm2
❑ MVA ≤ 1 cm2 in very severe MS
Diastolic pressure half time ≥ 150 ms
Diastolic pressure half time ≥ 220 ms with very severe MS
❑ Severe left atrial enlargement
❑ PASP > 30 mm Hg
Dyspnea on exertion
❑ Decreased exercise tolerance

References

  1. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, Gentile F; et al. (2021). "2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". Circulation. 143 (5): e72–e227. doi:10.1161/CIR.0000000000000923. PMID 33332150 Check |pmid= value (help).
  2. Nishimura, Rick A.; Otto, Catherine M.; Bonow, Robert O.; Carabello, Blase A.; Erwin, John P.; Guyton, Robert A.; O’Gara, Patrick T.; Ruiz, Carlos E.; Skubas, Nikolaos J.; Sorajja, Paul; Sundt, Thoralf M.; Thomas, James D. (2014). "2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary". Circulation. 129 (23): 2440–2492. doi:10.1161/CIR.0000000000000029. ISSN 0009-7322.
  3. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA; et al. (2014). "2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines". Circulation. doi:10.1161/CIR.0000000000000029. PMID 24589852.